These tumors are a model disease among NSCLC because of their very low tumor mutational burden, <3 mut/Mb, longest patient survival, currently >5 yr in median, and emerging molecular risk stratification based on the ALK fusion variant and TP53 status (Christopoulos et al. 2019b). This evidence concerns the gene ALK and neoplasm.